Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Andreas Busch

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

Novartis day

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

New drug due for launch in Europe in the second quarter

Bayer symbol

Bayer bulks up in women’s health again with non-hormonal contraceptive deal

If approved candidate would become a first-in-category therapy

Bayer symbol

Bayer extends alliance with Evotec in women’s health

Five-year research agreement focuses on polycystic ovary syndrome

- PMLiVE

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Was seeking approval in moderate-to-severe ulcerative colitis

Bayer symbol

Bayer, Merck’s high-risk heart failure drug comes good in phase 3

Significantly reduced the risk of hospitalisation or cardiovascular death

- PMLiVE

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

First wave of new molecular entities has potential to generate 14 approvals

Bristol Myers Squibb logo

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

Possible new treatment for difficult to treat cancer type

- PMLiVE

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Japanese pharma said it has plans to divest $10bn in non-core assests

- PMLiVE

Takeda offloads select portfolio to Acino ahead of Shire takeover

Hopes to reduce debt before acquistion completion

- PMLiVE

Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval

Will likely face competition soon from rival Rozlytrek

- PMLiVE

New hires at Bayer, Eisai and Accord Healthcare

The latest movers in pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links